Венозная тромбоэмболия: эпидемиологические, медико-социальные и экономические аспекты
DOI:
https://doi.org/10.52692/1857-0011.2022.1-72.12Ключевые слова:
венозный тромбоз, тромбоэмболия легочной артерии, факторы риска тромбозаАннотация
Венозная тромбоэмболия (ВТЭ) включает тромбоз глубоких вен нижних конечностей или таза и его осложнение в виде тромбоэмболии легочной артерии (ТЭЛА). ВТЭ широко распространена в клинической практике, особенно у пожилых людей, и связана с низкой выживаемостью, существенными затратами на лечение и высокой частотой рецидивов. Заболевание является комплексным (многофакторным), которое включает взаимодействие между приобретенными или наследственными предрасположенностями к тромбозам. Основные факторы риска венозного тромбоза включают госпитализацию по поводу хирургического вмешательства или острого заболевания, активный рак, неврологическое заболевание с неврологическими нарушениями, травмы или переломы, поверхностный и специфический венозный тромбоз у женщин - беременность и послеродовой период, оральные контрацептивы и гормональная терапия. Хотя в настоящее время определены независимые факторы риска венозного тромбоза, предикторы рецидива, доступны эффективные средства для первичной и вторичной профилактики, частота ВТЭ остается постоянной или даже увеличивается. В этом обзоре отражена текущая информацию об эпидемиологии венозной тромбоэмболии и факторах риска, тенденциях заболеваемости и рецидивов, выживае-мости, затратах при лечении.
Библиографические ссылки
Alexander T. Cohen et al. Venous thromboembolism (VTE) in Europe.The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007; 98: 756–764
Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015; 12(8): 464–474 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Euro Heart J. 2020; 41,543-603
Koton S. et al. Stroke incidence and mortality trends in US communities, 1987 to 2011. JAMA. 2014;312:259–268.
Kahn SR., Ducruet T., Lamping DL., Arsenault L., Miron MJ., Roussin A. et al. Prospective evaluation of health-related quality of life in patients with deep venous thrombosis. Arch Intern Med. 2005;165:1173–1178
Cushman M., Tsai AW., White RH., Heckbert SR., Rosamond WD, Enright P. et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the Longitudinal Investigation of Thromboembolism Etiology. Am J Med. 2004;117:19–25
Heit JA., Silverstein MD., Mohr DN., Petterson TM., O’Fallon WM., Melton LJ. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 1999;159:445–453
Tsai AW., Cushman M., Rosamond WD., Heckbert SR., Polak JF., Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: the Longitudinal Investigation of Thromboembolism Etiology. Arch Intern Med. 2002;162:1182–1189.
Stein PD., Kayali F., Olson RE., Milford CE. Pulmonary thromboembolism in Asians/Pacific Islanders in the United States: analysis of data from the National Hospital Discharge Survey and the United States Bureau of the Census. Am J Med. 2004;116:435–442
Cushman M. Epidemiology and Risk Factors for Venous Thrombosis, Semin Hematol. 2007; 44(2): 62–69
Lutsey PL., Cushman M., Steffen LM., Green D., Barr RG., Herrington D., et al. Plasma hemostatic factors and endothelial markers in four racial/ethnic groups: the MESA study. J. Thromb Haemost. 2006;4:2629–2635.
Huang W., Goldberg RJ., Anderson FA., Kiefe CI., Spencer FA. Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985–2009) Am. J. Med. 2014;127:829.e5–839.e5.
Stein PD., Beemath A., Olson RE. Obesity as a risk factor in venous thromboembolism. Am J Med. 2005;118:978–980.
Abdollahi M., Cushman M., Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost. 2003;89:493–498.
Cushman M., Kuller LH., Prentice R., Rodabough RJ., Psaty BM., Stafford RS. et al. Estrogen plus progestin and risk of venous thrombosis. Jama. 2004;292:1573–1580.
den Heijer M., Willems HP., Blom HJ., Gerrits WB., Cattaneo M., Eichinger S. et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. Blood. 2007;109:139–144.
Geerts WH., Pineo GF, Heit JA., Bergqvist D., Lassen MR., Colwell CW. et al. Prev.ention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:338S–400S.
White RH., Zhou H., Gage BF. Effect of age on the incidence of venous thromboembolism after major surgery. J Thromb Haemost. 2004;2:1327–1333
Blom JW., Vanderschoot JP., Oostindier MJ., Osanto S, van der Meer FJ, Rosendaal FR. Incidence of
venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006;4:529–535
Perez-Rodriguez E., Jimenez D., Diaz G., Perez-Walton I., Luque M., Guillen C. et al. Incidence of air travel-related pulmonary embolism at the Madrid-Barajas airport. Arch Intern Med. 2003;163:2766–2770
van Stralen KJ., Blom JW., Doggen CJ., Rosendaal FR. Strenuous sport activities involving the upper extremities increase the risk of venous thrombosis of the arm. J Thromb Haemost. 2005;3:2110–2111
Beasley R., Raymond N., Hill S., Nowitz M., Hughes R. eThrombosis: the 21st century variant of venous thromboembolism associated with immobility. Eur Respir J. 2003;21:374–376
Steffen LM., Folsom AR., Cushman M., Jacobs DR, Jr., Rosamond WD. Greater fish, fruit, and vegetable intakes are related to lower incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology. Circulation. 2007;115:188–195
Prandoni P., Bilora F., Marchiori A., Bernardi E., Petrobelli F., Lensing AW. et al. An association between atherosclerosis and venous thrombosis. N Engl J Med. 2003;348:1435–1441
Wichmann D.et al. Autopsy findings and venous thromboembolism in patients with COVID-19. Ann. Intern. Med. 2020 doi: 10.7326/M20-2003
Angelo P. et al., Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis. Thromb Res. 2020; 196: 67–74.
Vandenbroucke JP., Koster T., Briet E., Reitsma PH., Bertina RM., Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344:1453–1457
Spencer FA., et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J. Thromb. Thrombolysis. 2009;28:401–409
Heit JA. et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch. Intern. Med. 2000;160:761–768
Kovacs MJ., et al. Patients with a first symptomatic unprovoked deep vein thrombosis are at higher risk of recurrent venous thromboembolism than patients with a first unprovoked pulmonary embolism. J. Thromb. Haemost. 2010;8:1926–1932.
Biere-Rafi S. et al. Statin treatment and the risk of recurrent pulmonary embolism. Eur. Heart J. 2013;34:1800–1806
den Exter PL., et al. Risk profile and clinical outcome of symptomatic subsegmental acute pulmonary embolism. Blood. 2013;122:1144–1149
Baglin T. Management of thrombophilia: who to screen? Pathophysiol Haemost Thromb. 2003;33:401–404.
Christiansen SC., Cannegieter SC., Koster T., Vandenbroucke JP., Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. Jama. 2005;293:2352–2361
Shrivastava S., Ridker PM., Glynn RJ., Goldhaber SZ. Moll S, Bounameaux H, et al. D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost. 2006;4:1208–1214.
Kahn SR., Ginsberg JS. The post-thrombotic syndrome: current knowledge, controversies, and directions for future research. Blood Rev. 2002;16:155–165
Cohoon KP., et al. Costs of venous thromboembolism associated with hospitalization for medical illness. Am. J. Manag. Care. 2015;21:e255–e263.
Oscar Miro et al., Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome. Euro Heart J. 2021 00, 1–16
Alex C. Spyropoulos, Mark Goldin et al., HEP-COVID Trial, Systemic Anticoagulation With Full Dose Low Molecular Weight Heparin (LMWH) vs. Prophylactic or Intermediate Dose LMWH in High Risk COVID-19 Patients. ESC Congress 2021.
Загрузки
Опубликован
Выпуск
Раздел
Лицензия
Copyright (c) 2022 Вестник Академии Наук Молдовы. Медицина
![Лицензия Creative Commons](http://i.creativecommons.org/l/by/4.0/88x31.png)
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.